STAAR Surgical (STAA) has drawn investor attention after appointing Warren Foust as Chief Executive Officer and to its Board of Directors on 4 August 2026, following an extensive global search.

The CEO appointment comes after a stretch where STAAR Surgical’s 30 day share price return declined 11.78% and the 1 year total shareholder return fell 10.33%, while the 5 year total shareholder return was down 82.55%. This points to fading long term momentum despite a modest 2.20% year to date share price gain.

If you are reassessing your exposure to medical and vision care themes, it can also be useful to see what is happening across healthcare focused AI plays via the 41 healthcare AI stocks.

Bulls see STAAR Surgical’s new leadership and profitable growth reset as a base for a rerating, while bears point to years of weak shareholder returns. Which case do the current valuation markers support next?

Most Popular Narrative: 18.7% Undervalued

At a last close of $24.12, the most followed narrative for STAAR Surgical places fair value at $29.67, which frames the current reset under new leadership.

The analysts have a consensus price target of $29.67 for STAAR Surgical based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $23.0.

Want to see what sits behind that higher fair value for STAAR Surgical? The narrative focuses on a sharp earnings swing and richer margins, and explores which revenue path and profitability mix need to hold for this to add up.

Result: Fair Value of $29.67 (UNDERVALUED)

However, STAAR Surgical still carries key risks, including reliance on a single distributor in China and ongoing competitive pressure that could disrupt the recovery story.

Another View on STAAR Surgical Valuation

The analyst narrative points to STAAR Surgical trading below a $29.67 fair value, yet the market is still paying a rich P/S of 4.1x. That is higher than the US Medical Equipment industry at 2.9x, the peer average at 2.4x, and the fair ratio of 3.4x. Is the current price leaving much margin for error if growth or profitability assumptions slip?

Next Steps

The mixed sentiment around STAAR Surgical makes this a moment to move quickly and check the underlying data for yourself rather than rely on headlines alone. To see why some investors are still optimistic, review the 2 key rewards.

Looking for more investment ideas beyond STAAR Surgical?

If STAAR Surgical has you rethinking your portfolio, do not stop here. Use the Simply Wall St screener to surface fresh ideas before other investors react.

• Target potential upside by scanning companies that combine quality and attractive pricing through the 51 high quality undervalued stocks.
• Strengthen portfolio resilience by focusing on businesses with cleaner finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Aim for both income and staying power by reviewing companies featured in the 7 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.